Premium
Combination Therapy for Early Alzheimer's Disease: What Are We Waiting for?
Author(s) -
Doraiswamy P. Murali,
Steffens David C.
Publication year - 1998
Publication title -
journal of the american geriatrics society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.992
H-Index - 232
eISSN - 1532-5415
pISSN - 0002-8614
DOI - 10.1111/j.1532-5415.1998.tb04556.x
Subject(s) - medicine , ginkgo biloba , disease , vasoactive , alzheimer's disease , rivastigmine , intensive care medicine , cholinesterase , combination therapy , bioinformatics , dementia , donepezil , pharmacology , biology
The practical pharmacological approaches currently available to palliate the cognitive and functional losses in early Alzheimer's disease (AD) include Cholinesterase inhibitors (ChEI), antioxidants (e.g., vitamin E), anti‐inflammatory agents, estrogen, seligiline, vasoactive agents, and ginkgo biloba. Reviewing available data on these therapies and using models from medical illnesses such as cancer and hypertension, we highlight the urgent need for evaluating combination therapies in early AD.